Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
Wim H.J. Kruit(Erasmus MC), Ulrich Keilholz(German Cancer Research Center), Frédéric Lehmann(Télécom Paris), Michele Maio(University of Siena), Vincent Brichard(GlaxoSmithKline (Belgium)), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Alexander M.M. Eggermont(University Medical Center Utrecht), Alan Spatz(Jewish General Hospital), Thierry Dorval(Centre Hospitalier Universitaire Brugmann), Laurent Mortier, Stefan Suciu(St James's University Hospital), Caroline Robert(Institut Gustave Roussy), Jamila Louahed(Centre Hospitalier Universitaire Brugmann), Juergen C. Becker(Centre Hospitalier Universitaire Brugmann), Jean‐Jacques Grob(Aix-Marseille Université), Brigitte Dréno(Nantes Université)
Cited by 222
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k